Ameriderm Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$7,753	1
2023	Research	$51,350	5
2022	Research	$25,278	5
2021	Research	$79,067	16
2020	Research	$96,004	8
2019	Research	$84	1

Breakdown

Who paid Research payments · program years 2019–2024

Ucb SA $246,803 29 payments
E.R. Squibb & Sons, L.L.C. $7,666 2 payments
Novartis Pharmaceuticals Corporation $4,997 4 payments
Pfizer Inc. $70 1 payment

Studies the money was for Research payments · program years 2019–2024

A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoria $63,686 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $59,553 7 payments
A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $55,565 9 payments
A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. $50,767 8 payments
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa $7,750 1 payment
Phase II Umbrella AD - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis $7,666 2 payments
A Phase 3, Randomized, Double-Blind, Placebocontrolled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $5,894 2 payments
A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa Sunrise $4,997 4 payments
A PHASE 3, MULTICENTER, randomized, double-blind, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, parallel-group study to EVALUATE the EFFICACY AND safety of bimekizumab in adult subjects with moderate to $3,587 1 payment
A Phase 2A Multicenter Randomized Doubleblind Placebocontrolled 16Week Study Evaluating the Safety and Efficacy of Pf06650833 Pf06700841 and Pf06826647 in Adults With Moderate to Severe Hidradenitis Suppurativa $70 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.